Jun.25.2024
R & D

European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab

 This material is intended to notify the press release issued on June 21 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click https://www.bms.com/media/press-releases.html for the original press release.